title: Initial concentration-time profile of gentamicin determines efficacy against Enterobacter cloacae ATCC 13047.
abstract: In vitro studies were designed to investigate the influence of peak drug concentration (Cmax), the area under the concentration-time curve (AUC), and, consequently, the trough concentration on the bactericidal effects of gentamicin against Enterobacter cloacae (MIC, 0.5 mg/liter) by simulating bolus versus infusion administration and bolus dosing with altered drug clearance. Bacteria in the lag phase were exposed to gentamicin concentration-time profiles modelling either bolus or infusion dosing (AUC constant, Cmax changing) with 30-min postdose peak concentrations (Cpeak30) of 4, 6, 8, and 10 mg/liter or bolus dosing with normal and double drug clearance (Cmax constant, AUC changing) corresponding to normal clearance profiles with Cpeak30 of 6 and 8 mg/liter. Exposure to gentamicin caused early bactericidal effects apparent by 2 h, followed by variable bacteriostatic and recovery phases. Exposure to bolus profiles resulted in greater bactericidal activity than the corresponding infusion profile up to a Cpeak30 of 8 mg/liter. At a Cpeak30 of 10 mg/liter, there were no differences in bactericidal effect. Double clearance profiles had a reduced bactericidal effect at 6 mg/liter compared to the corresponding normal clearance profile, but no differences in bactericidal effect were observed for 8-mg/liter double and normal clearance profiles. These results suggest that the initial exposure (i.e., 0 to 30 min) is a more important determinant for bacterial killing than the AUC or trough concentration for this bacterium. Subject to confirmation of these findings with other gram-negative bacteria, to optimize aminoglycoside efficacy the initial exposure (Cmax) should be maximized by giving higher doses or bolus administration at intervals which may not produce detectable trough concentrations. Clinical trials with a broad range of patients, especially those with higher clearance, would confirm these in vitro observations and define optimal dosing recommendations.
authors.affiliation: Department of Pharmacy, Alfred Healthcare Group, Prahran, Victoria, Australia.
authors.forename: C R
authors.initials: CR
authors.lastname: Rayner
authors.forename: L L
authors.initials: LL
authors.lastname: Ioannides-Demos
authors.forename: J A
authors.initials: JA
authors.lastname: Brien
authors.forename: L L
authors.initials: LL
authors.lastname: Liolios
authors.forename: W J
authors.initials: WJ
authors.lastname: Spicer
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000494:pharmacology; D019540:Area Under Curve; D016972:Enterobacter cloacae / Q000187:drug effects*; D005839:Gentamicins / Q000008:administration & dosage* / Q000494:pharmacology; D008657:Metabolic Clearance Rate; D008826:Microbial Sensitivity Tests; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D005839:Gentamicins